

# Soldano Ferrone

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8570171/soldano-ferrone-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

199  
papers

10,611  
citations

58  
h-index

98  
g-index

220  
ext. papers

12,470  
ext. citations

7.5  
avg. IF

6.17  
L-index

#	Paper	IF	Citations
199	Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. <i>Advances in Immunology</i> , <b>2000</b> , 74, 181-273	5.6	863
198	Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. <i>Trends in Immunology</i> , <b>1995</b> , 16, 487-94		413
197	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1420-1435	24.4	302
196	HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. <i>Trends in Molecular Medicine</i> , <b>1999</b> , 5, 178-86		279
195	NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 1251-63	15.9	260
194	Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 800-13	12.9	244
193	Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4390-9	2.2	243
192	Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. <i>International Journal of Cancer</i> , <b>1981</b> , 28, 293-300	7.5	221
191	Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. <i>American Journal of Pathology</i> , <b>1999</b> , 154, 745-54	5.8	220
190	Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 2552-60	12.9	194
189	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , <b>2015</b> , 75, 2200-10	10.1	175
188	Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3890-5	12.9	174
187	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. <i>Cancer Cell</i> , <b>2019</b> , 35, 221-237.e8	24.3	157
186	HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. <i>Cancer Research</i> , <b>2006</b> , 66, 9281-9	10.1	146
185	Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. <i>Critical Reviews in Immunology</i> , <b>2004</b> , 24, 267-96	1.8	145
184	Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. <i>Journal of Immunology</i> , <b>2003</b> , 171, 1918-26	5.3	144
183	Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. <i>Cancer</i> , <b>2001</b> , 92, 369-76	6.4	142

182	Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	140
181	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 1853-64	7.4	139
180	Programmed cell death ligand 1 expression in osteosarcoma. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 690-698	6.2	135
179	Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6174-84	12.9	135
178	Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 197-206	7.4	134
177	Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. <i>Journal of Extracellular Vesicles</i> , <b>2018</b> , 7, 1435138	16.4	132
176	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 470-8	12.9	124
175	CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1496-512	9.7	117
174	Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. <i>Journal of Cell Biology</i> , <b>2004</b> , 165, 881-91	7.3	116
173	CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. <i>Pigment Cell and Melanoma Research</i> , <b>2011</b> , 24, 1148-57	4.5	109
172	Genetic evolution of T-cell resistance in the course of melanoma progression. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6593-604	12.9	106
171	Immune selective pressure and HLA class I antigen defects in malignant lesions. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 227-36	7.4	89
170	Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?. <i>Blood</i> , <b>2004</b> , 103, 3122-30	2.2	89
169	Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. <i>Journal of Experimental Medicine</i> , <b>1999</b> , 190, 205-15	16.6	89
168	Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. <i>Transplantation</i> , <b>1982</b> , 34, 18-23	1.8	88
167	Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. <i>Advances in Cancer Research</i> , <b>2005</b> , 93, 189-234	5.9	86
166	Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. <i>Journal of Immunology</i> , <b>2005</b> , 174, 1462-71	5.3	86
165	Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. <i>Cancer Research</i> , <b>2008</b> , 68, 8066-75	10.1	85

164	Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5229-5237	12.9	85
163	Functional and clinical relevance of chondroitin sulfate proteoglycan 4. <i>Advances in Cancer Research</i> , <b>2010</b> , 109, 73-121	5.9	83
162	Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells <b>2014</b> , 2, 25		82
161	Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. <i>Oncogene</i> , <b>2005</b> , 24, 4634-44	9.2	81
160	Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. <i>Journal of Immunology</i> , <b>2014</b> , 192, 523-32	5.3	80
159	Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. <i>Surgery</i> , <b>2007</b> , 141, 41-50	3.6	80
158	Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. <i>Nature Communications</i> , <b>2014</b> , 5, 5639	17.4	77
157	Blocking the formation of radiation-induced breast cancer stem cells. <i>Oncotarget</i> , <b>2014</b> , 5, 3743-55	3.3	77
156	Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 1721-7	12.9	77
155	CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 707-716	12.9	74
154	Ipilimumab in the treatment of metastatic melanoma: management of adverse events. <i>OncoTargets and Therapy</i> , <b>2014</b> , 7, 203-9	4.4	74
153	Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. <i>Scientific Reports</i> , <b>2020</b> , 10, 92	4.9	74
152	NK cells and T cells cooperate during the clinical course of colorectal cancer. <i>Oncology</i> , <b>2014</b> , 3, e952197	7.2	73
151	HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. <i>Neoplasia</i> , <b>2014</b> , 16, 31-42	6.4	72
150	Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 529-40	7.4	72
149	Constitutive and TNF $\alpha$ -inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	67
148	Structural polymorphism of human DR antigens. <i>Nature</i> , <b>1979</b> , 279, 436-7	50.4	64
147	Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. <i>Scientific Reports</i> , <b>2017</b> , 7, 2290	4.9	62

146	Immunomodulating and Immuno-resistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. <i>Immunological Investigations</i> , <b>2017</b> , 46, 221-238	2.9	59
145	Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. <i>Oncotarget</i> , <b>2016</b> , 7, 7390-402	3.3	59
144	Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 4043-51	12.9	59
143	T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 962-71	12.9	58
142	SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 798-808	12.9	58
141	A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. <i>Cancer Research</i> , <b>2010</b> , 70, 3027-33	10.1	58
140	LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1816-26	12.9	57
139	Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 11-20	12.9	57
138	CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5352-63	12.9	57
137	TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. <i>International Journal of Cancer</i> , <b>2001</b> , 95, 23-8	7.5	56
136	A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2012</b> , 127, 420-5	4.9	55
135	A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. <i>Journal of Immunological Methods</i> , <b>2005</b> , 299, 139-51	2.5	55
134	Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription. <i>Cancer Research</i> , <b>2019</b> , 79, 1069-1084	10.1	55
133	STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 936-45	12.5	54
132	Association of HL-A antigens and D-microglobulin at the cellular and molecular level. <i>Immunogenetics</i> , <b>1975</b> , 2, 183-197	3.2	54
131	CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3753-62	12.9	51
130	Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2668-78	12.9	51
129	Stimulation of human T lymphocytes by PHA-activated autologous T lymphocytes: analysis of the role of Ia-like antigens with monoclonal antibodies. <i>Immunogenetics</i> , <b>1981</b> , 12, 267-74	3.2	50

128	The role of cancer stem cells in the modulation of anti-tumor immune responses. <i>Seminars in Cancer Biology</i> , <b>2018</b> , 53, 189-200	12.7	48
127	Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. <i>Cancer Research</i> , <b>2011</b> , 71, 7410-22	10.1	47
126	Melanoma cells inhibit NK cell functions. <i>Cancer Research</i> , <b>2012</b> , 72, 5428-9; author reply 5430	10.1	47
125	B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. <i>EBioMedicine</i> , <b>2019</b> , 47, 33-43	8.8	45
124	Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 26562-75	5.4	45
123	B7-H3: An Attractive Target for Antibody-based Immunotherapy. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1227-1235	11.35	44
122	HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. <i>OncolImmunology</i> , <b>2017</b> , 6, e1171447	7.2	43
121	Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. <i>Journal of Immunology</i> , <b>2000</b> , 165, 3275-83	5.3	43
120	Defective HLA class I antigen processing machinery in cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 999-1009	7.4	42
119	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5520-5533	12.9	40
118	Distribution of antigenic determinants recognized by three monoclonal antibodies (Q2/70, Q5/6 and Q5/13) on human Ia-like alloantigens and on their subunits. <i>Immunogenetics</i> , <b>1981</b> , 12, 175-82	3.2	38
117	B7-H3-targeted Pb radioimmunotherapy of ovarian cancer in preclinical models. <i>Nuclear Medicine and Biology</i> , <b>2017</b> , 47, 23-30	2.1	37
116	Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. <i>Oral Oncology</i> , <b>2016</b> , 58, 52-8	4.4	37
115	Lymphocytotoxic antibodies in systemic lupus erythematosus patients and their relatives: reactivity with the HLA antigenic molecular complex. <i>Arthritis and Rheumatism</i> , <b>1980</b> , 23, 265-72		37
114	Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. <i>International Journal of Oncology</i> , <b>2012</b> , 40, 965-74	4.4	36
113	Long Noncoding RNA MPRL Promotes Mitochondrial Fission and Cisplatin Chemosensitivity via Disruption of Pre-miRNA Processing. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3673-3688	12.9	35
112	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2644-2655	12.9	34
111	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. <i>Cancer Letters</i> , <b>2017</b> , 409, 9-19	9.9	33

110	Molecular and Functional Profiles of Exosomes From HPV(+) and HPV(-) Head and Neck Cancer Cell Lines. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 445	5.3	33
109	Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. <i>Cancer</i> , <b>2003</b> , 97, 2203-11	6.4	31
108	Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. <i>Gynecologic Oncology</i> , <b>2014</b> , 132, 203-10	4.9	30
107	FC[Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 457	8.4	30
106	Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. <i>Veterinary Journal</i> , <b>2011</b> , 190, e26-e30	2.5	30
105	Antitumor Activity of BRAF Inhibitor and IFN[Combination in BRAF-Mutant Melanoma. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	29
104	Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 224	8.4	27
103	EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3. <i>Oncolimmunology</i> , <b>2013</b> , 2, e27215	7.2	27
102	Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. <i>Cancer Immunology, Immunotherapy</i> , <b>2000</b> , 49, 314-8	7.4	27
101	Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram. <i>Cell Communication and Signaling</i> , <b>2020</b> , 18, 36	7.5	26
100	Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. <i>Nuclear Medicine and Biology</i> , <b>2018</b> , 58, 67-73	2.1	26
99	Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. <i>Journal of Immunological Methods</i> , <b>2017</b> , 450, 73-80 <sup>5</sup>	2.5	23
98	Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. <i>International Journal of Cancer</i> , <b>2000</b> , 89, 153-9	7.5	23
97	HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. <i>European Journal of Immunology</i> , <b>2016</b> , 46, 409-19	6.1	23
96	Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. <i>Journal of Immunology</i> , <b>2005</b> , 174, 7104-10	5.3	21
95	CSPG4 as a prognostic biomarker in chordoma. <i>Spine Journal</i> , <b>2016</b> , 16, 722-7	4	21
94	Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. <i>Oncolimmunology</i> , <b>2015</b> , 4, e1023975	7.2	20
93	Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	19

92	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. <i>Cancers</i> , <b>2020</b> , 12,	6.6	19
91	Radioimmunodetection of Melanoma: Preliminary Results of a Prospective Study. <i>International Journal of Biological Markers</i> , <b>1986</b> , 1, 47-54	2.8	18
90	Decreased expression of mitochondrial miR-5787 contributes to chemoresistance by reprogramming glucose metabolism and inhibiting MT-CO3 translation. <i>Theranostics</i> , <b>2019</b> , 9, 5739-5754	12.1	18
89	Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 37646-37656	3.3	17
88	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature <b>2018</b> , 6, 126		17
87	Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. <i>Expert Opinion on Therapeutic Targets</i> , <b>2015</b> , 19, 1339-50	6.4	16
86	Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. <i>Cancer Research</i> , <b>2005</b> , 65, 6976-83	10.1	16
85	Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. <i>Journal of Investigative Dermatology</i> , <b>1999</b> , 112, 744-50	4.3	16
84	Analysis of the NIH workshop monoclonal antibodies to human melanoma antigens. <i>Hybridoma</i> , <b>1982</b> , 1, 473-82		16
83	CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. <i>Frontiers in Neuroscience</i> , <b>2021</b> , 15, 662064	5.1	16
82	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 609-617	3.1	16
81	The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 903-912	4.3	16
80	Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 4266-4281	15.9	15
79	HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. <i>Methods in Molecular Biology</i> , <b>2020</b> , 2055, 325-350	1.4	15
78	Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1982-93	7.9	14
77	The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. <i>Immunity</i> , <b>2021</b> , 54, 132-150.e9	32.3	14
76	lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter. <i>IScience</i> , <b>2020</b> , 23, 100835	6.1	13
75	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. <i>Nature Communications</i> , <b>2018</b> , 9, 5097	17.4	13



74	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , <b>2019</b> , 24, e275-e283	5.7	12
73	Dendritic cell maturation in HCV infection: altered regulation of MHC class I antigen processing-presenting machinery. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 242-51	13.4	12
72	Distribution of a cross-species melanoma-associated antigen in normal and neoplastic human tissues. <i>Journal of Investigative Dermatology</i> , <b>1985</b> , 85, 340-6	4.3	12
71	Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP. <i>Oncotarget</i> , <b>2017</b> , 8, 113837-113846	3.3	12
70	Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1102, 523-35	1.4	12
69	In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 236-247	7.5	12
68	Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. <i>Journal of Extracellular Vesicles</i> , <b>2021</b> , 10, e12063	16.4	12
67	Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3141-3153	12.9	12
66	ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells. <i>Scientific Reports</i> , <b>2017</b> , 7, 9687	4.9	11
65	Rabbit complement in the lymphocytotoxicity test. <i>Tissue Antigens</i> , <b>1977</b> , 9, 223-6		11
64	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 182-191	9.7	11
63	Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919855491	5.4	10
62	Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors. <i>Molecular Therapy - Oncolytics</i> , <b>2019</b> , 15, 30-37	6.4	10
61	Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , <b>2014</b> , 85, 953-61	4.6	10
60	Hidden immunotherapy targets challenge dogma. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 99ps38	17.5	10
59	Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. <i>Oncotarget</i> , <b>2016</b> , 7, 2070-9	3.3	9
58	CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2531-2538	7.5	9
57	Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform. <i>Immunologic Research</i> , <b>2018</b> , 66, 584-604	4.3	9

56	Methods for improving the immunogenicity and efficacy of cancer vaccines. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 765-784	5.4	8
55	Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. <i>Seminars in Oncology</i> , <b>2014</b> , 41, 685-99	5.5	8
54	Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1051-1059	13.4	8
53	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2018</b> , 18, 166-181	2.2	7
52	Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 441-453	12.5	7
51	HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. <i>Trends in Cancer</i> , <b>2021</b> , 7, 1089-1101	12.5	7
50	Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma <b>2020</b> , 8,		6
49	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , <b>2018</b> , 77, 92-97	4.4	6
48	AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. <i>Oncotarget</i> , <b>2016</b> , 7, 60872-60884	3.3	6
47	B7-H3 targeted antibody-based immunotherapy of malignant diseases. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 587-602	5.4	6
46	Emerging BRAF inhibitors for melanoma. <i>Expert Opinion on Emerging Drugs</i> , <b>2013</b> , 18, 431-43	3.7	5
45	Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 701-701	2.2	5
44	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6321-6334	12.9	5
43	Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 577-588	6.1	5
42	A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3757-3771	12.9	5
41	Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells. <i>Hepatology</i> , <b>2021</b> , 74, 550-565	11.2	5
40	Improving the Clinical Significance of Preclinical Immunotherapy Studies through Incorporating Tumor Microenvironment-like Conditions. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4448-4453	12.9	4
39	IL-15/B7-H3 TriKEs-Based Immunotherapy for Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , <b>2019</b> , 229, S176	4.4	4

38	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. <i>Journal of Translational Medicine</i> , <b>2021</b> , 19, 17	8.5	4
37	Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , <b>2013</b> , 25-47	0.3	4
36	Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. <i>Cancers</i> , <b>2019</b> , 11,	6.6	3
35	Cancer Stem Cells: The Players of Immune Evasion from Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , <b>2019</b> , 223-249	0.3	3
34	A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , <b>2020</b> , 18, 255	8.5	3
33	Therapeutic monoclonal antibodies: introduction. <i>Seminars in Oncology</i> , <b>2014</b> , 41, 556-8	5.5	3
32	High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes. <i>Cellular Immunology</i> , <b>2017</b> , 320, 29-37	4.4	3
31	Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts. <i>Oncology Research</i> , <b>2015</b> , 22, 117-21	4.8	3
30	Sera from volunteers immunized by planned blood transfusions as source of DR cytotoxic typing reagents. <i>Immunological Investigations</i> , <b>1979</b> , 8, 93-106		3
29	B7-H3-targeted Radioimmunotherapy of Human Cancer. <i>Current Medicinal Chemistry</i> , <b>2020</b> , 27, 4016-4038	3	3
28	Multidisciplinary approach to patient with malignant melanoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2013</b> , 13, 887-900	2.2	3
27	Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 561390	8.4	3
26	Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
25	Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors. <i>Clinical Orthopaedics and Related Research</i> , <b>2021</b> , 479, 1373-1382	2.2	3
24	Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2837-2847	12.9	3
23	Novel ANO5 mutation c.1067G>T (p.C356F) identified by whole genome sequencing in a big family with atypical gnathodiaphyseal dysplasia. <i>Head and Neck</i> , <b>2019</b> , 41, 230-238	4.2	3
22	A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. <i>Expert Review of Dermatology</i> , <b>2006</b> , 1, 805-823		2
21	Variability in immune infiltrates and HLA expression in cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 230-230	2.2	2

20	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , <b>2020</b> , 18, 346	8.5	2
19	Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. <i>Cells</i> , <b>2021</b> , 10,	7.9	2
18	Risk Prediction Model for Cisplatin-Associated Acute Kidney Injury. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2453-2454	2.2	2
17	HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab.. <i>Pathology and Oncology Research</i> , <b>2022</b> , 28, 1610297	2.6	2
16	Changes in serum ganglioside and antibody levels in soft tissue sarcoma: are they the cause or the effect of tumor progression?. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2002</b> , 8, 369-70	2.2	1
15	Activation of the complement system by H-2 alloantisera: Differential susceptibility to lysis of thymocytes and lymphocytes. <i>Immunogenetics</i> , <b>1975</b> , 2, 199-203	3.2	1
14	The major portion of rabbit antibody to serum HLA-A9 antigens is directed to allospecificity. <i>Tissue Antigens</i> , <b>1978</b> , 12, 153-5		1
13	The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells.. <i>Blood</i> , <b>2006</b> , 108, 4550-4550	2.2	1
12	Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12015-12015	2.2	1
11	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	1
10	Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. <b>2022</b> , 10,		1
9	Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. <b>2022</b> , 10,		1
8	Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.. <i>Frontiers in Veterinary Science</i> , <b>2022</b> , 9, 803093	3.1	0
7	High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 598001	5.3	0
6	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 240	12.8	0
5	Response to the letter to the editors by Ottaiano et al.: Ñetuximab-dependent ADCC in cancer: dream or reality? <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 1609-1610	7.4	
4	The Antileukemic Effect of NK and NK-T Cells Against Chronic Myelogenous Leukemia Is Dominated by Interactions between Activating Molecules and Their Ligands Which Overcome Inhibitory KIR-MHC Class I Interaction.. <i>Blood</i> , <b>2004</b> , 104, 2948-2948	2.2	
3	Dose-seeking and efficacy study of combination BRAFi and high-dose IFN (HDI) for therapy of advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS9110-TPS9110	2.2	

- 2 Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. *Journal of Clinical Oncology*, **2014**, 32, TPS9105-TPS9105 2.2
- 1 Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients.. *Journal of Clinical Oncology*, **2017**, 35, 6058-6058 2.2